Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Boschetti

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 4, 2016
Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitisAnne-Claire Frin, Jérôme Filippi, Gilles Boschetti, et al.
BMC Cancer|March 18, 2014
GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III studyOlivier Glehen, Guillaume Passot, Laurent Villeneuve, et al.
Digestive Diseases and Sciences|September 16, 2020
No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose IntensificationStephane Paul, Nicolas Williet, Stéphane Nancey, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2014
Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatmentGilles Boschetti, Stéphane Nancey, Driffa Moussata, et al.
Digestive Diseases (Basel, Switzerland)|August 22, 2018
Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion ReactionsIsabelle Pauchard, Stéphane Nancey, Florence Hacard, et al.
European Journal of Gastroenterology & Hepatology|January 16, 2010
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?Gilles Boschetti, Thomas Walter, Valérie Hervieu, et al.
Inflammatory Bowel Diseases|February 8, 2024
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional StudyLea Derbey, Anne Laure Charlois, Anthony Buisson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 22, 2009
CD4+ T cells and Lactobacillus casei control relapsing colitis mediated by CD8+ T cellsFeriel Hacini-Rachinel, Stephane Nancey, Gilles Boschetti, et al.
Inflammatory Bowel Diseases|August 20, 2010
Blockade of LTB(4) /BLT(1) pathway improves CD8(+) T-cell-mediated colitisStephane Nancey, Gilles Boschetti, Feriel Hacini, et al.
Clinics and Research in Hepatology and Gastroenterology|September 30, 2024
Real-life effectiveness of allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulizing refractory Crohn's diseaseMaria Alonso-Gomez, Anne Laure Charlois, Eddy Cotte, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 4, 2016
Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitisAnne-Claire Frin, Jérôme Filippi, Gilles Boschetti, et al.
BMC Cancer|March 18, 2014
GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III studyOlivier Glehen, Guillaume Passot, Laurent Villeneuve, et al.
Digestive Diseases and Sciences|September 16, 2020
No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose IntensificationStephane Paul, Nicolas Williet, Stéphane Nancey, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2014
Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatmentGilles Boschetti, Stéphane Nancey, Driffa Moussata, et al.
Digestive Diseases (Basel, Switzerland)|August 22, 2018
Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion ReactionsIsabelle Pauchard, Stéphane Nancey, Florence Hacard, et al.
European Journal of Gastroenterology & Hepatology|January 16, 2010
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?Gilles Boschetti, Thomas Walter, Valérie Hervieu, et al.
Inflammatory Bowel Diseases|February 8, 2024
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional StudyLea Derbey, Anne Laure Charlois, Anthony Buisson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 22, 2009
CD4+ T cells and Lactobacillus casei control relapsing colitis mediated by CD8+ T cellsFeriel Hacini-Rachinel, Stephane Nancey, Gilles Boschetti, et al.
Inflammatory Bowel Diseases|August 20, 2010
Blockade of LTB(4) /BLT(1) pathway improves CD8(+) T-cell-mediated colitisStephane Nancey, Gilles Boschetti, Feriel Hacini, et al.
Clinics and Research in Hepatology and Gastroenterology|September 30, 2024
Real-life effectiveness of allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulizing refractory Crohn's diseaseMaria Alonso-Gomez, Anne Laure Charlois, Eddy Cotte, et al.
Pageof 7